Replies to post #169633 on Biotech Values

[DewDiligence]

…I think ABBV is also testing its regimen for 12 or 24 weeks in cirrhotic patients.

Correct; all cirrhotic patents in ABBV/ENTA’s TURQUOISE-2 study are DAA-naïve and will receive 3 DAA’s plus ribavirin (#msg-93647264).